CRUCIANI, M., P. L. WHITE, C. MENGOLI, J. LÖFFLER, C. O. MORTON, L. KLINGSPOR, D. BUCHHEIDT, J. MAERTENS, W. J. HEINZ, T. R. ROGERS, Barbora WEINBERGEROVÁ, A. WARRIS, DEA. LOCKHART, B. JONES, C. CORDONNIER, J. P. DONELLY a R. A. BARNES. The impact of anti-mould prophylaxis on Aspergillus PCR blood testing for the diagnosis of invasive aspergillosis. Journal of Antimicrobial Chemotherapy. Oxford: Oxford University Press, 2021, roč. 76, č. 3, s. 635-638. ISSN 0305-7453. Dostupné z: https://dx.doi.org/10.1093/jac/dkaa498.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název The impact of anti-mould prophylaxis on Aspergillus PCR blood testing for the diagnosis of invasive aspergillosis.
Autoři CRUCIANI, M., P. L. WHITE (garant), C. MENGOLI, J. LÖFFLER, C. O. MORTON, L. KLINGSPOR, D. BUCHHEIDT, J. MAERTENS, W. J. HEINZ, T. R. ROGERS, Barbora WEINBERGEROVÁ (203 Česká republika, domácí), A. WARRIS, DEA. LOCKHART, B. JONES, C. CORDONNIER, J. P. DONELLY a R. A. BARNES.
Vydání Journal of Antimicrobial Chemotherapy, Oxford, Oxford University Press, 2021, 0305-7453.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30303 Infectious Diseases
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.758
Kód RIV RIV/00216224:14110/21:00121104
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1093/jac/dkaa498
UT WoS 000620821900013
Klíčová slova anglicky Aspergillus PCR blood testing; invasive aspergillosis; anti-mould prophylaxis
Štítky 14110212, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 7. 4. 2021 10:44.
Anotace
Background: The performance of the galactomannan enzyme immunoassay (GM-EIA) is impaired in patients receiving mould-active antifungal therapy. The impact of mould-active antifungal therapy on Aspergillus PCR testing needs to be determined. Objectives: To determine the influence of anti-mould prophylaxis (AMP) on the performance of PCR blood testing to aid the diagnosis of proven/probable invasive aspergillosis (IA). Methods: As part of the systematic review and meta-analysis of 22 cohort studies investigating Aspergillus PCR blood testing in 2912 patients at risk of IA, subgroup analysis was performed to determine the impact of AMP on the accuracy of Aspergillus PCR. The incidence of IA was calculated in patients receiving and not receiving AMP. The impact of two different positivity thresholds (requiring either a single PCR positive test result or >= 2 consecutive PCR positive test results) on accuracy was evaluated. Meta-analytical pooling of sensitivity and specificity was performed by Logistic mixed-model regression. Results: In total, 1661 (57%) patients received prophylaxis. The incidence of IA was 14.2%, significantly Lower in the prophylaxis group (11%-12%) compared with the non-prophylaxis group (18%-19%) (P< 0.001). The use of AMP did not affect sensitivity, but significantly decreased specificity [single PCR positive result threshold: 26% reduction (P= 0.005); >= 2 consecutive PCR positive results threshold: 12% reduction (P= 0.019)]. Conclusions: Contrary to its influence on GM-EIA, AMP significantly decreases Aspergillus PCR specificity, without affecting sensitivity, possibly as a consequence of AMP Limiting the clinical progression of IA and/or Leading to false-negative GM-EIA results, preventing the classification of probable IA using the EORTC/MSGERC definitions.
VytisknoutZobrazeno: 3. 10. 2024 23:11